To summarize, the study shows that targeting the CBP/β-catenin interaction with PRI-724 effectively downregulates survivin and promotes apoptosis in melanoma cells, especially in those resistant to trametinib, a MEK inhibitor. The gene discussed is MAP2K7; the disease is melanoma.